Lapaquistat acetate - CAS 189060-13-7
Catalog number: B0084-061834
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C33H41ClN2O9
Molecular Weight:
645.14
COA:
Inquire
Targets:
Others
Description:
Lapaquistat acetate, also referred as TAK475, is a squalene synthase inhibitor. As a cholesterol-lowering drug, Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-061834 5 mg $498 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
White to off-white crystalline solid
Synonyms:
2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid; (1-(2-(1-(2-carboxyoxy-1,1-dimethylethyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydrobenzo(e)(1,4)oxazepin-3-yl)acetyl)piperidin-4-yl)acetic acid; 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid; lapaquistat; TAK 475; TAK-475; TAK475
MSDS:
Inquire
Application:
A novel squalene synthase inhibitor
InChIKey:
CMLUGNQVANVZHY-POURPWNDSA-N
InChI:
1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-10,16,21,27,30H,11-15,17-19H2,1-5H3,(H,39,40)/t27-,30-/m1/s1
Canonical SMILES:
CC(=O)OCC(C)(C)CN1C2=C(C=C(C=C2)Cl)C(OC(C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC
1.Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T1, Teshima K1, Kondo T1, Tagawa Y1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Feb 2. [Epub ahead of print]
The pharmacokinetics of TAK-475 (lapaquistat acetate), a squalene synthase inhibitor, was investigated in rats and dogs. After oral administration of 14C-labeled TAK-475 ([14C]TAK-475) to rats and dogs at a dose of 10 mg/kg, the bioavailability (BA) was relatively low at 3.5 and 8.2%, respectively. The main component of the radioactivity in the plasma was M-I, which has a comparable pharmacological activity to TAK-475 in vitro. The radioactivity in the portal plasma after intraduodenal administration of [14C]TAK-475 to portal vein-cannulated rat was also mainly M-I, suggesting that most of the TAK-475 was hydrolyzed to M-I during the permeable process in the intestine. The concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration of [14C]TAK-475 to rats. The main elimination route of the radioactivity was fecal excretion after oral administration of [14C]TAK-475 to rats and dogs, and the absorbed radioactivity was mainly excreted via the bile as M-I in rats.
2.Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
Davidson MH1. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
There remains an unmet need to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients who are maximized on current therapy or intolerant to statins. Several novel agents have been developed to lower LDL-C, either as monotherapy or in combination with statins. These novel therapies include squalene synthase inhibitors, microsomal triglyceride transfer protein inhibitors, and antisense apolipoprotein B. Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety.
3.Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Ebihara T1, Takeuchi T1, Moriya Y1, Tagawa Y1, Kondo T1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Mar 24. [Epub ahead of print]
TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor and M-I is a pharmacologically active metabolite of TAK-475. Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorption process and the concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration to rats. In the present study, the mechanism of the hepatic uptake of M-I was investigated.The uptake studies of 14C-labeled M-I into rat and human hepatocytes indicated that the uptakes of M-I were concentrative, temperature-dependent and saturable in both species with Km values of 4.7 and 2.8 μmol/L, respectively. M-I uptake was also inhibited by cyclosporin A, an inhibitor for hepatic uptake transporters including organic anion transporting polypeptide (OATP). In the human hepatocytes, M-I uptake was hardly inhibited by estrone 3-sulfate as an inhibitor for OATP1B1, and most of the M-I uptake was Na+-independent.
4.Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S1, Frishman WH. Cardiol Rev. 2009 Mar-Apr;17(2):70-6. doi: 10.1097/CRD.0b013e3181885905.
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases. The most popular agents for cholesterol reduction are the statin drugs, which are competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme in the hepatic biosynthesis of cholesterol. Although relatively safe and effective, the available statins can cause elevations in liver enzymes and myopathy. Squalene synthase is another enzyme that is downstream to HMG-CoA reductase in the cholesterol synthesis pathway and modulates the first committed step of hepatic cholesterol biosynthesis at the final branch point of the cholesterol biosynthetic pathway. Squalene epoxidase and oxidosqualene cyclase are other enzymes that act distally to squalene synthase. Pharmacologic inhibitors of these downstream enzymes have been developed, which may reduce low-density lipoprotein cholesterol and reduce the myopathy side effect seen with upstream inhibition of HMG-CoA.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 22033-87-0 TRO 19622

TRO 19622
(CAS: 22033-87-0)

Olesoxime (TRO19622) is an experimental neuroprotective drug. It is the lead compound of Trophos' cholesterol-oxime compound family of mitochondrial pore modula...

CAS 939983-14-9 p53 and MDM2 proteins-interaction-inhibitor racemic

p53 and MDM2 proteins-interaction-inhibi
(CAS: 939983-14-9)

p53 and MDM2 proteins-interaction-inhibitor racemic is an inhibitor of the interaction between p53 and MDM2 proteins.

Mirin
(CAS: 1198097-97-0)

Mirin is a Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor. .

LY 249933
(CAS: 123250-77-1)

LY 249933 is a bio-active molecular under the development of Eli Lilly. It has positive inotropic activity as a cardioselective 1,4-dihydropyridine compound.

CAS 152646-95-2 Ono-4007 sodium salt

Ono-4007 sodium salt
(CAS: 152646-95-2)

The sodium salt form of Ono-4007, a partial analogue of bacterial lipopolysaccharide, has been found to stimulate tumor necrosis factor so that could be useful ...

CAS 2375-03-3 6A-methylprednisolone 21-hemisuccinate*sodium

6A-methylprednisolone 21-hemisuccinate*s
(CAS: 2375-03-3)

6α-Methylprednisolone 21-hemisuccinate, a derivative of prednisolone, is a kind of glucocorticoids. It has been developed for having longer half-life than that ...

CAS 98769-84-7 Reboxetine mesylate

Reboxetine mesylate
(CAS: 98769-84-7)

Reboxetine is a norepinephrine reuptake inhibitor with Ki of 8.2 nM.

CAS 87-89-8 Inositol

Inositol
(CAS: 87-89-8)

Inositol is a chemical compound found in many foods, especially oranges and cantaloupe. It is well-absorbed and relatively bioavailable. It is a component of me...

CAS 93-14-1 Guaifenesin

Guaifenesin
(CAS: 93-14-1)

Guaifenesin is thought to act as an expectorant.

CAS 115103-54-3 Tiagabine

Tiagabine
(CAS: 115103-54-3)

Tiagabine is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor.

CAS 53-06-5 Cortisone

Cortisone
(CAS: 53-06-5)

Cortisone is a synthetic steroid hormone which are widely used for the treatment of inflammation; a corticosterone analog that has approximately twice the anti-i...

CAS 16200-50-3 PYR-0503

PYR-0503
(CAS: 16200-50-3)

PYR-0503, a pyrrole compound, could be commonly used in production of sorts of important compounds like some anticancer drugs and porphyrins.

CS-M1996
(CAS: 876708-01-9)

CS-M1996 is a 4′-Azidocytidine analogue. It can inhibit Hepatitis C virus replication.

GnRH-I

GnRH-I, a small 10 amino acid long peptide (decapeptide) from the hypothalamus, has previously been demonstrated and shown to be biologically active in the immu...

CAS 213400-34-1 UPF-648

UPF-648
(CAS: 213400-34-1)

Potent and selective inhibitor of kynurenine-3-monooxygenase (KMO, or kynurenine hydroxylase) activity (IC50: 20 nM); Active (+)-(1S,2S)-enantiomer; Useful tool...

CAS 119-41-5 Efloxate

Efloxate
(CAS: 119-41-5)

Efloxate, a flavone derivative, could be effective in the treatment of chronic coronary insufficiency and angina pectoris for acting as a vasodilator.

CAS 223580-51-6 Tiadinil

Tiadinil
(CAS: 223580-51-6)

Tiadinil is a plant activator of systemic acquired resistance, boosts the production of herbivore-induced plant volatiles; insecticide agent.

CAS 54857-86-2 TOFA

TOFA
(CAS: 54857-86-2)

TOFA, also called as RMI14514 or MDL14514, is a cell-permeable, potent, reversible, and competitive allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). TOF...

CAS 1445879-21-9 GSK2837808A

GSK2837808A
(CAS: 1445879-21-9)

GSK2837808A is a potent and specific lactate dehydrogenase A (LDHA) with IC50values of 1.9 and 14 nM for LDHA and LDHB, respectively and inhibits lactate produc...

Usistapide
(CAS: 403989-79-7)

Usistapide is a Microsomal triglyceride transfer protein inhibitor under development for the treatment of obesity and type 2 diabetes.

Chemical Structure

CAS 189060-13-7 Lapaquistat acetate

Quick Inquiry

Verification code

Featured Items